Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
|Videos|October 19, 2020
Feel Well, Fill Well: Refills During the Pandemic
Author(s)John J. Miller, MD
Dr Miller offers advice on making sure you have enough medication when self-isolating.
Advertisement
Dr Miller is Medical Director, Brain Health, Exeter, NH; Editor in Chief, Psychiatric Times; Staff Psychiatrist, Seacoast Mental Health Center, Exeter, NH; Consulting Psychiatrist, Exeter Hospital, Exeter, NH; Consulting Psychiatrist, Insight Meditation Society, Barre, MA.
Advertisement
Related to this article
Ketamine, esketamine, and ECT can rapidly ease suicidal thoughts, but evidence for preventing attempts or deaths remains limited—see what’s proven.
Nearly half of US adults who drink and use cannabis combine them at once; cannabis use disorder drives the trend, signaling urgent screening needs.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Learn how clozapine, lithium, ketamine, and antidepressants fit into suicide prevention, from rapid crisis relief to long-term risk reduction.
Courts cite teen brain science to soften sentences; experts warn generalized neuroscience overreaches and adult responsibility stabilizes by 18 to 20.
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Real-World Burden of Adult ADHD
2
Dissecting Algorithms of the Mind: Toward Precision Psychiatry in Schizophrenia
3
Fewer Than 1 in 5 Young Patients With First-Episode Psychosis Adhere to Antipsychotics
4
Muscarinic Mechanisms Continue a New Chapter in Schizophrenia Treatment
5